Sequence-Selective Covalent CaaX-Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Oncogenic Ras proteins are key drivers in numerous life-threatening cancers.
• Targeting Ras proteins with small-molecule inhibitors has proven challenging due to their protein-protein interaction mechanisms.
• Current therapeutic strategies have limited success in inhibiting Ras-driven cancers.

Purpose of the Study:

• To develop an alternative strategy for inhibiting oncogenic Ras proteins.
• To explore a novel approach that targets Ras protein activation prerequisite.
• To design sequence-selective supramolecular receptors for Ras and Rheb proteins.

Main Methods:

• Developing supramolecular receptors targeting the C-terminal farnesyl transferase recognition unit.
• Utilizing sequence-selective binding to inhibit Ras and Rheb protein activation.
• Covalently modifying the essential cysteine residue within the CaaX-box.

Main Results:

• Demonstrated a novel strategy to prevent Ras protein farnesylation and membrane insertion.
• Successfully designed supramolecular receptors capable of sequence-selective binding.
• Showcased the potential for inhibiting Ras and Rheb protein activation via CaaX-box modification.

Conclusions:

• The developed supramolecular receptor strategy offers a promising alternative for targeting oncogenic Ras proteins.
• This approach bypasses the difficulties associated with inhibiting protein-protein interactions.
• Provides a new potential therapeutic avenue for treating Ras-driven cancers.